Preview

Эндокринная хирургия

Расширенный поиск

Проект клинических рекомендаций «Инциденталома надпочечника»

https://doi.org/10.14341/serg12712

Полный текст:

Аннотация

Более широкое применение и техническое совершенствование процедур визуализации брюшной полости в последние годы привело к все более частому обнаружению образований надпочечников — инциденталом, требующих, в свою очередь, исключения гормональной активности и злокачественности.

Клинические рекомендации — это основной рабочий инструмент практикующего врача, как специалиста, так и врача узкой практики. Лаконичность, структурированность сведений об определенной нозологии, методов ее диагностики и лечения, базирующихся на принципах доказательной медицины, позволяют в короткий срок дать тот или иной ответ на интересующий вопрос специалисту, добиваться максимальной эффективности и персонализации лечения. Эти клинические рекомендации включают в себя данные о распространенности, этиологии, рентгенологических особенностях и оценке гормонального статуса инцидиенталом надпочечников. Кроме того, настоящие клинические рекомендации содержат информацию о показаниях к хирургическому лечению, послеоперационной реабилитации и последующем наблюдении.

Об авторах

Д. Г. Бельцевич
Национальный медицинский исследовательский центр эндокринологии
Россия

Бельцевич Дмитрий Германович, д.м.н., профессор, eLibrary SPIN: 4475-6327



Е. А. Трошина
Национальный медицинский исследовательский центр эндокринологии
Россия

Трошина Екатерина Анатольевна, д.м.н., профессор, член-корреспондент РАН, eLibrary SPIN: 8821-8990



Г. А. Мельниченко
Национальный медицинский исследовательский центр эндокринологии
Россия

Мельниченко Галина Афанасьевна, д.м.н., профессор, академик РАН, eLibrary SPIN: 8615-0038



Н. М. Платонова
Национальный медицинский исследовательский центр эндокринологии
Россия

Платонова Надежда Михайловна, д.м.н., eLibrary SPIN: 4053-3033



Д. О. Ладыгина
Национальный медицинский исследовательский центр эндокринологии
Россия

Ладыгина Дарья Олеговна, к.м.н., eLibrary SPIN: 7958-9435



А. Шевэ
Национальный медицинский исследовательский центр эндокринологии
Россия

Шевэ Анастасия, аспирант, Россия, 117036, Москва, ул. Дм. Ульянова, д. 11, тел.: +7-962-993-27-63, eLibrary SPIN: 2459-0540



Список литературы

1. Бельцевич Д.Г., Кузнецов Н.С., Солдатова Т.В., Ванушко В.Э. Инциденталома надпочечников // Эндокринная хирургия. — 2009. — Т. 4. — №1. — С. 19–23. doi: https://doi.org/10.14341/2306-3513-2009-1-19-23

2. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-G34. doi: https://doi.org/10.1530/EJE-16-0467

3. Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004;25(2):309-340. doi: https://doi.org/10.1210/er.2002-0031

4. Berruti A, Baudin E, Gelderblom H, et al. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii131-vii138. doi: https://doi.org/10.1093/annonc/mds231

5. Clark OH, Benson AB 3rd, Berlin JD, et al. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009;7(7):712-747. doi: https://doi.org/10.6004/jnccn.2009.0050

6. Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. Endocr Rev. 1995;16(4):460-484. doi: https://doi.org/10.1210/edrv-16-4-460

7. Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006;29(4):298-302. doi: https://doi.org/10.1007/BF03344099

8. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601-610. doi: https://doi.org/10.1056/NEJMcp065470

9. Cawood TJ, Hunt PJ, O’Shea D, et al. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?. Eur J Endocrinol. 2009;161(4):513-527. doi: https://doi.org/10.1530/EJE-09-0234

10. Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1-G46. Published 2018 Oct 1. doi: https://doi.org/10.1530/EJE-18-0608

11. Ahmed AA, Thomas AJ, Ganeshan DM, et al. Adrenal cortical carcinoma: pathology, genomics, prognosis, imaging features, and mimics with impact on management. Abdom Radiol (NY). 2020;45(4):945-963. doi: https://doi.org/10.1007/s00261-019-02371-y

12. Gross MD, Shapiro B. Clinical review 50: Clinically silent adrenal masses. J Clin Endocrinol Metab. 1993;77(4):885-888. doi: https://doi.org/10.1210/jcem.77.4.8408461

13. Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164(6):851-870. doi: https://doi.org/10.1530/EJE-10-1147

14. Terzolo M, Bovio S, Reimondo G, et al. Subclinical Cushing’s syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am. 2005;34(2):423-x. doi: https://doi.org/10.1016/j.ecl.2005.01.008

15. Terzolo M, Bovio S, Pia A, et al. Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. Eur J Endocrinol. 2005;153(2):307-315. doi: https://doi.org/10.1530/eje.1.01959

16. Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002;87(11):4872-4878. doi: https://doi.org/10.1210/jc.2001-011766

17. Morelli V, Masserini B, Salcuni AS, et al. Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol (Oxf ). 2010;73(2):161-166. doi: https://doi.org/10.1111/j.1365-2265.2010.03794.x

18. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85(2):637-644. doi: https://doi.org/10.1210/jcem.85.2.6372

19. Kirkby-Bott J, Brunaud L, Mathonet M, et al. Ectopic hormone-secreting pheochromocytoma: a francophone observational study. World J Surg. 2012;36(6):1382-1388. doi: https://doi.org/10.1007/s00268-012-1488-1

20. Мельниченко Г.А., Алексеев Б.Я., Бельцевич Д.Г., и др. Клинические рекомендации. Рак коры надпочечников (адренокортикальный рак). 2020.

21. Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807-2831. doi: https://doi.org/10.1210/jc.2015-1818

22. Libè R, Dall’Asta C, Barbetta L, et al. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol. 2002;147(4):489-494. doi: https://doi.org/10.1530/eje.0.1470489

23. Elhassan YS, Alahdab F, Prete A, et al. Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis. Ann Intern Med. 2019;171(2):107-116. doi: https://doi.org/10.7326/M18-3630

24. Кузнецов Н.С., Бельцевич Д.Г., Ванушко В.Э., и др. Дифференциальная диагностика инциденталом надпочечников // Эндокринная хирургия. — 2011. — Т. 5. — №1. — С.5–16. doi: https://doi.org/10.14341/2306-3513-2011-1-5-16

25. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540. doi: https://doi.org/10.1210/jc.2008-0125

26. Ceccato F, Antonelli G, Frigo AC, et al. First-line screening tests for Cushing’s syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS. J Endocrinol Invest. 2017;40(7):753-760. doi: https://doi.org/10.1007/s40618-017-0644-8

27. Penezić Z, Zarković M, Vujović S, et al. Value of assessing adrenocorticotropic hormone (ACTH) levels in differential diagnosis of hypercorticism. Med Pregl. 2004;57(7-8):335-342. doi: https://doi.org/10.2298/mpns0408335p

28. Olsen H, Kjellbom A, Löndahl M, Lindgren O. Suppressed ACTH Is Frequently Unrelated to Autonomous Cortisol Secretion in Patients With Adrenal Incidentalomas. J Clin Endocrinol Metab. 2019;104(2):506-512. doi: https://doi.org/10.1210/jc.2018-01029

29. Di Dalmazi G, Berr CM, Fassnacht M, et al. Adrenal function after adrenalectomy for subclinical hypercortisolism and Cushing’s syndrome: a systematic review of the literature. J Clin Endocrinol Metab. 2014;99(8):2637-2645. doi: https://doi.org/10.1210/jc.2014-1401

30. Prete A, Paragliola RM, Bottiglieri F, et al. Factors predicting the duration of adrenal insufficiency in patients successfully treated for Cushing disease and nonmalignant primary adrenal Cushing syndrome. Endocrine. 2017;55(3):969-980. doi: https://doi.org/10.1007/s12020-016-1007-5

31. Hurtado MD, Cortes T, Natt N, et al. Extensive clinical experience: Hypothalamic-pituitary-adrenal axis recovery after adrenalectomy for corticotropin-independent cortisol excess. Clin Endocrinol (Oxf ). 2018;89(6):721-733. doi: https://doi.org/10.1111/cen.13803

32. Schalin-Jäntti C, Raade M, Hämäläinen E, Sane T. A 5-Year Prospective Follow-Up Study of Lipid-Rich Adrenal Incidentalomas: No Tumor Growth or Development of Hormonal Hypersecretion. Endocrinol Metab (Seoul). 2015;30(4):481-487. doi: https://doi.org/10.3803/EnM.2015.30.4.481

33. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942. doi: https://doi.org/10.1210/jc.2014-1498

34. Därr R, Kuhn M, Bode C, et al. Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. Endocrine. 2017;56(3):495-503. doi: https://doi.org/10.1007/s12020-017-1300-y

35. Mullins F, O’Shea P, FitzGerald R, Tormey W. Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal. Clin Chem Lab Med. 2011;50(1):105-110. Published 2011 Oct 8. doi: https://doi.org/10.1515/CCLM.2011.742

36. Мельниченко Г.А., Трошина Е.А., Бельцевич Д.Г., и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике и лечению феохромоцитомы/параганглиомы // Эндокринная хирургия. — 2015. — Т. 9. — №3. — С. 15–33. doi: https://doi.org/10.14341/serg2015315-33

37. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287(11):1427-1434. doi: https://doi.org/10.1001/jama.287.11.1427

38. Sbardella E, Grossman AB. Pheochromocytoma: An approach to diagnosis. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101346. doi: https://doi.org/10.1016/j.beem.2019.101346

39. Yu R, Wei M. False positive test results for pheochromocytoma from 2000 to 2008. Exp Clin Endocrinol Diabetes. 2010;118(9):577-585. doi: https://doi.org/10.1055/s-0029-1237699

40. Neary NM, King KS, Pacak K. Drugs and pheochromocytoma--don’t be fooled by every elevated metanephrine. N Engl J Med. 2011;364(23):2268-2270. doi: https://doi.org/10.1056/NEJMc1101502#SA1

41. Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from falsepositive test results. J Clin Endocrinol Metab. 2003;88(6):2656-2666. doi: https://doi.org/10.1210/jc.2002-030005

42. Meyer-Rochow GY, Schembri GP, Benn DE, et al. The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol. 2010;17(2):392-400. doi: https://doi.org/10.1245/s10434-009-0850-5

43. Derlin T, Busch JD, Wisotzki C, et al. Intraindividual comparison of 123I-mIBG SPECT/MRI, 123I-mIBG SPECT/CT, and MRI for the detection of adrenal pheochromocytoma in patients with elevated urine or plasma catecholamines. Clin Nucl Med. 2013;38(1):e1-e6. doi: https://doi.org/10.1097/RLU.0b013e318263923d

44. Sane T, Schalin-Jäntti C, Raade M. Is biochemical screening for pheochromocytoma in adrenal incidentalomas expressing low unenhanced attenuation on computed tomography necessary?. J Clin Endocrinol Metab. 2012;97(6):2077-2083. doi: https://doi.org/10.1210/jc.2012-1061

45. Buitenwerf E, Korteweg T, Visser A, et al. Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study. Eur J Endocrinol. 2018;178(5):431-437. doi: https://doi.org/10.1530/EJE-18-0006

46. Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab. 2015;100(1):1-10. doi: https://doi.org/10.1210/jc.2014-3663

47. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-1248. doi: https://doi.org/10.1016/j.jacc.2005.01.015

48. Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126-148. doi: https://doi.org/10.1111/joim.12831

49. Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med. 1981;141(12):1589-1593.

50. McKenna TJ, Sequeira SJ, Heffernan A, et al. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab. 1991;73(5):952-957. doi: https://doi.org/10.1210/jcem-73-5-952

51. Stowasser M, Gordon RD. Primary aldosteronism-careful investigation is essential and rewarding. Mol Cell Endocrinol. 2004;217(1-2):33-39. doi: https://doi.org/10.1016/j.mce.2003.10.006

52. Veldhuizen GP, Alnazer RM, Kroon AA, de Leeuw PW. Confounders of the aldosterone-to-renin ratio when used as a screening test in hypertensive patients: A critical analysis of the literature. J Clin Hypertens (Greenwich). 2021;23(2):201-207. doi: https://doi.org/10.1111/jch.14117

53. O’Shea PM, Griffin TP, Denieffe S, Fitzgibbon MC. The aldosterone to renin ratio in the diagnosis of primary aldosteronism: Promises and challenges. Int J Clin Pract. 2019;73(7):e13353. doi: https://doi.org/10.1111/ijcp.13353

54. Schilbach K, Junnila RK, Bidlingmaier M. Aldosterone to Renin Ratio as Screening Tool in Primary Aldosteronism. Exp Clin Endocrinol Diabetes. 2019;127(2-03):84-92. doi: https://doi.org/10.1055/a-0672-0836

55. Stowasser M, Ahmed AH, Pimenta E, et al. Factors affecting the aldosterone/renin ratio. Horm Metab Res. 2012;44(3):170-176. doi: https://doi.org/10.1055/s-0031-1295460

56. Widimský J, Bruthans J, Wohlfahrt P, et al. Primary aldosteronism in a general population sample. The Czech post-MONICA study. Blood Press. 2020;29(3):191-198. doi: https://doi.org/10.1080/08037051.2020.1723406

57. Douillard C, Houillier P, Nussberger J, Girerd X. SFE/SFHTA/ AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps. Ann Endocrinol (Paris). 2016;77(3):192-201. doi: https://doi.org/10.1016/j.ando.2016.02.003

58. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf ). 2007;66(5):607-618. doi: https://doi.org/10.1111/j.1365-2265.2007.02775.x

59. Mosso L, Carvajal C, González A, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42(2):161-165. doi: https://doi.org/10.1161/01.HYP.0000079505.25750.11

60. Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi: https://doi.org/10.1210/jc.2015-4061

61. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89(3):1045-1050. doi: https://doi.org/10.1210/jc.2003-031337

62. Monticone S, Burrello J, Tizzani D, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017;69(14):1811-1820. doi: https://doi.org/10.1016/j.jacc.2017.01.052

63. Kokko E, Nevalainen PI, Choudhary MK, et al. Aldosteroneto-renin ratio is related to arterial stiffness when the screening criteria of primary aldosteronism are not met. Sci Rep. 2020;10(1):19804. Published 2020 Nov 13. doi: https://doi.org/10.1038/s41598-020-76718-7

64. Kisaka T, Ozono R, Ishida T, et al. Association of elevated plasma aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension. J Hypertens. 2012;30(12):2322-2330. doi:10.1097/HJH.0b013e328359862d

65. Shapiro Y, Boaz M, Matas Z, et al. The association between the renin-angiotensin-aldosterone system and arterial stiffness in young healthy subjects. Clin Endocrinol (Oxf ). 2008;68(4):510-512. doi: https://doi.org/10.1111/j.1365-2265.2008.03176.x

66. Cain JP, Tuck ML, Williams GH, et al. The regulation of aldosterone secretion in primary aldosteronism. Am J Med. 1972;53(5):627-637. doi: https://doi.org/10.1016/0002-9343(72)90158-1

67. d’Alva CB, Abiven-Lepage G, Viallon V, et al. Sex steroids in androgen-secreting adrenocortical tumors: clinical and hormonal features in comparison with non-tumoral causes of androgen excess. Eur J Endocrinol. 2008;159(5):641-647. doi: https://doi.org/10.1530/EJE-08-0324

68. Di Dalmazi G. Hyperandrogenism and Adrenocortical Tumors. Front Horm Res. 2019;53:92-99. doi: https://doi.org/10.1159/000494905

69. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(12):4551-4564. doi: https://doi.org/10.1210/jc.2013-3020

70. Chortis V, Bancos I, Nijman T, et al. Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2020;105(3):e307-e318. doi: https://doi.org/10.1210/clinem/dgz141

71. Claahsen-van der Grinten HL, Hermus AR, Otten BJ. Testicular adrenal rest tumours in congenital adrenal hyperplasia. Int J Pediatr Endocrinol. 2009;2009:624823. doi: https://doi.org/10.1155/2009/624823

72. Bourdeau I, El Ghorayeb N, Gagnon N, Lacroix A. MANAGEMENT OF ENDOCRINE DISEASE: Differential diagnosis, investigation and therapy of bilateral adrenal incidentalomas. Eur J Endocrinol. 2018;179(2):R57-R67. doi: https://doi.org/10.1530/EJE-18-0296

73. Шевэ А., Селиванова Л.С., Кузнецов Н.С., и др. Иммуногистохимическое исследование экспрессии аберрантных/эутопических рецепторов у пациентов с макронодулярной гиперплазией надпочечников // Проблемы эндокринологии. — 2020. — Т. 66. — №6. — С. 4-12. doi: https://doi.org/10.14341/probl12516

74. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364-389. doi: https://doi.org/10.1210/jc.2015-1710

75. Del Monte P, Bernasconi D, Bertolazzi L, et al. Increased 17 alpha-hydroxyprogesterone response to ACTH in silent adrenal adenoma: cause or effect?. Clin Endocrinol (Oxf ). 1995;42(3):273-277. doi: https://doi.org/10.1111/j.1365-2265.1995.tb01875.x

76. Jaresch S, Kornely E, Kley HK, Schlaghecke R. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1992;74(3):685-689. doi: https://doi.org/10.1210/jcem.74.3.1311000

77. Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline [published correction appears in J Clin Endocrinol Metab. 2019 Jan 1;104(1):39-40]. J Clin Endocrinol Metab. 2018;103(11):4043-4088. doi: https://doi.org/10.1210/jc.2018-01865

78. Al-Hawary MM, Francis IR, Korobkin M. Non-invasive evaluation of the incidentally detected indeterminate adrenal mass. Best Pract Res Clin Endocrinol Metab. 2005;19(2):277-292. doi: https://doi.org/10.1016/j.beem.2004.09.002

79. McCarthy CJ, McDermott S, Blake MA. Adrenal Imaging: Magnetic Resonance Imaging and Computed Tomography. Front Horm Res. 2016;45:55-69. doi: https://doi.org/10.1159/000442313

80. Warda MH, Shehata SM, Zaiton F. Chemical-shift MRI versus washout CT for characterizing adrenal incidentalomas. Clin Imaging. 2016;40(4):780-787. doi: https://doi.org/10.1016/j.clinimag.2016.02.006

81. Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab. 2005;90(2):871-877. doi: https://doi.org/10.1210/jc.2004-1627

82. Dinnes J, Bancos I, Ferrante di Ruffano L, et al. MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175(2):R51-R64. doi: https://doi.org/10.1530/EJE-16-0461

83. Sabet FA, Majdzadeh R, Mostafazadeh Davani B, Heidari K, Soltani A. Likelihood ratio of computed tomography characteristics for diagnosis of malignancy in adrenal incidentaloma: systematic review and meta-analysis. J Diabetes Metab Disord. 2016;15:12. Published 2016 Apr 21. doi: https://doi.org/10.1186/s40200-016-0224-z

84. Terzolo M, Reimondo G, Bovio S, Angeli A. Subclinical Cushing’s syndrome. Pituitary. 2004;7(4):217-223. doi: https://doi.org/10.1007/s11102-005-4024-6

85. Fan J, Tang J, Fang J, et al. Ultrasound imaging in the diagnosis of benign and suspicious adrenal lesions. Med Sci Monit. 2014;20:2132-2141. Published 2014 Nov 3. doi: https://doi.org/10.12659/MSM.890800

86. Petersenn S, Richter PA, Broemel T, et al. Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. Eur J Endocrinol. 2015;172(4):415-422. doi: https://doi.org/10.1530/EJE-14-0916

87. Cistaro A, Niccoli Asabella A, Coppolino P, et al. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies — a multicenter experience. Hell J Nucl Med. 2015;18(2):97-102. doi: https://doi.org/10.1967/s002449910202

88. Guerin C, Pattou F, Brunaud L, et al. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study. J Clin Endocrinol Metab. 2017;102(7):2465-2472. doi: https://doi.org/10.1210/jc.2017-00254

89. Nakajo M, Jinguji M, Nakajo M, et al. Texture analysis of FDG PET/CT for differentiating between FDG-avid benign and metastatic adrenal tumors: efficacy of combining SUV and texture parameters. Abdom Radiol (NY). 2017;42(12):2882-2889. doi: https://doi.org/10.1007/s00261-017-1207-3

90. Kim SJ, Lee SW, Pak K, et al. Diagnostic accuracy of 18F-FDG PET or PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. Br J Radiol. 2018;91(1086):20170520. doi: https://doi.org/10.1259/bjr.20170520

91. Timmers HJ, Chen CC, Carrasquillo JA, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94(12):4757-4767. doi: https://doi.org/10.1210/jc.2009-1248

92. Alencar GA, Fragoso MC, Yamaga LY, et al. (18)F-FDG-PET/CT imaging of ACTH-independent macronodular adrenocortical hyperplasia (AIMAH) demonstrating increased (18)F-FDG uptake. J Clin Endocrinol Metab. 2011;96(11):3300-3301. doi: https://doi.org/10.1210/jc.2011-1397

93. Arellano RS, Harisinghani MG, Gervais DA, et al. Image-guided percutaneous biopsy of the adrenal gland: review of indications, technique, and complications. Curr Probl Diagn Radiol. 2003;32(1):3-10. doi: https://doi.org/10.1067/cdr.2003.120002

94. Harisinghani MG, Maher MM, Hahn PF, et al. Predictive value of benign percutaneous adrenal biopsies in oncology patients. Clin Radiol. 2002;57(10):898-901. doi: https://doi.org/10.1053/crad.2002.1054

95. Bancos I, Tamhane S, Shah M, et al. DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175(2):R65-R80. doi: https://doi.org/10.1530/EJE-16-0297

96. Молашенко Н.В., Платонова Н.М., Бельцевич Д.Г., и др. Дифференциальная диагностика инциденталом надпочечников // Ожирение и метаболизм. — 2016. — Т. 13. — №.4 — С. 39-44. doi: 10.14341/OMET2016439-44

97. Anagnostis P, Efstathiadou Z, Polyzos SA, et al. Long term follow-up of patients with adrenal incidentalomas — a single center experience and review of the literature. Exp Clin Endocrinol Diabetes. 2010;118(9):610-616. doi: https://doi.org/10.1055/s-0029-1237704

98. Yilmaz H, Tütüncü NB, Sahin M. Two-year follow-up of thirty-two non-functional benign adrenal incidentalomas. J Endocrinol Invest. 2009;32(11):913-916. doi: https://doi.org/10.1007/BF03345772

99. Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010;58(4):609-615. doi: https://doi.org/10.1016/j.eururo.2010.06.024

100. Cooper AB, Habra MA, Grubbs EG, et al. Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma?. Surg Endosc. 2013;27(11):4026-4032. doi: https://doi.org/10.1007/s00464-013-3034-0

101. Donatini G, Caiazzo R, Do Cao C, et al. Long-term survival after adrenalectomy for stage I/II adrenocortical carcinoma (ACC): a retrospective comparative cohort study of laparoscopic versus open approach. Ann Surg Oncol. 2014;21(1):284-291. doi: https://doi.org/10.1245/s10434-013-3164-6

102. Fosså A, Røsok BI, Kazaryan AM, et al. Laparoscopic versus open surgery in stage I-III adrenocortical carcinoma -- a retrospective comparison of 32 patients. Acta Oncol. 2013;52(8):1771-1777. doi: https://doi.org/10.3109/0284186X.2013.765065

103. Lombardi CP, Raffaelli M, De Crea C, et al. Open versus endoscopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: results of a multiinstitutional Italian survey. Surgery. 2012;152(6):1158-1164. doi: https://doi.org/10.1016/j.surg.2012.08.014

104. Miller BS, Ammori JB, Gauger PG, Broome JT, Hammer GD, Doherty GM. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma. World J Surg. 2010;34(6):1380-1385. doi: https://doi.org/10.1007/s00268-010-0532-2

105. Miller BS, Gauger PG, Hammer GD, Doherty GM. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery. 2012;152(6):1150-1157. doi: https://doi.org/10.1016/j.surg.2012.08.024

106. Mir MC, Klink JC, Guillotreau J, et al. Comparative outcomes of laparoscopic and open adrenalectomy for adrenocortical carcinoma: single, high-volume center experience. Ann Surg Oncol. 2013;20(5):1456-1461. doi: https://doi.org/10.1245/s10434-012-2760-1

107. Porpiglia F, Fiori C, Daffara F, et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol. 2010;57(5):873-878. doi: https://doi.org/10.1016/j.eururo.2010.01.036

108. Langenhuijsen J, Birtle A, Klatte T, et al. Surgical Management of Adrenocortical Carcinoma: Impact of Laparoscopic Approach, Lymphadenectomy, and Surgical Volume on Outcomes-A Systematic Review and Meta-analysis of the Current Literature [published correction appears in Eur Urol Focus. 2018 Apr;4(3):461]. Eur Urol Focus. 2016;1(3):241-250. doi: https://doi.org/10.1016/j.euf.2015.12.001

109. Morelli V, Minelli L, Eller-Vainicher C, et al. Predictability of hypoadrenalism occurrence and duration after adrenalectomy for ACTH-independent hypercortisolism. J Endocrinol Invest. 2018;41(4):485-493. doi: https://doi.org/10.1007/s40618-017-0788-6

110. Debillon E, Velayoudom-Cephise FL, Salenave S, et al. Unilateral Adrenalectomy as a First-Line Treatment of Cushing’s Syndrome in Patients With Primary Bilateral Macronodular Adrenal Hyperplasia. J Clin Endocrinol Metab. 2015;100(12):4417-4424. doi: https://doi.org/10.1210/jc.2015-2662

111. Osswald A, Quinkler M, Di Dalmazi G, et al. Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy. J Clin Endocrinol Metab. 2019;104(7):2985-2993. doi: https://doi.org/10.1210/jc.2018-02204

112. Sheikh-Ahmad M, Dickstein G, Matter I, et al. Unilateral Adrenalectomy for Primary Bilateral Macronodular Adrenal Hyperplasia: Analysis of 71 Cases. Exp Clin Endocrinol Diabetes. 2020;128(12):827-834. doi: https://doi.org/10.1055/a-0998-7884

113. Xu Y, Rui W, Qi Y, et al. The role of unilateral adrenalectomy in corticotropin-independent bilateral adrenocortical hyperplasias. World J Surg. 2013;37(7):1626-1632. doi: https://doi.org/10.1007/s00268-013-2059-9

114. Bernini GP, Moretti A, Oriandini C, et al. Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. Br J Cancer. 2005;92(6):1104-1109. doi: https://doi.org/10.1038/sj.bjc.6602459

115. Barzon L, Scaroni C, Sonino N, et al. Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab. 1999;84(2):520-526. doi: https://doi.org/10.1210/jcem.84.2.5444

116. Giordano R, Marinazzo E, Berardelli R, et al. Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur J Endocrinol. 2010;162(4):779-785. doi: https://doi.org/10.1530/EJE-09-0957

117. Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003;149(4):273-285. doi: https://doi.org/10.1530/eje.0.1490273

118. Berland LL, Silverman SG, Gore RM, et al. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol. 2010;7(10):754-773. doi: https://doi.org/10.1016/j.jacr.2010.06.013

119. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. doi: https://doi.org/10.1016/j.ejca.2008.10.026

120. Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing’s syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab. 2008;93(5):1553-1562. doi: https://doi.org/10.1210/jc.2008-0139


Для цитирования:


Бельцевич Д.Г., Трошина Е.А., Мельниченко Г.А., Платонова Н.М., Ладыгина Д.О., Шевэ А. Проект клинических рекомендаций «Инциденталома надпочечника». Эндокринная хирургия. 2021;15(1):4-26. https://doi.org/10.14341/serg12712

For citation:


Beltsevich D.G., Troshina E.A., Melnichenko G.A., Platonova N.M., Ladygina D.O., Chevais A. Draft of the clinical practice guidelines “Adrenal incidentaloma”. Endocrine Surgery. 2021;15(1):4-26. (In Russ.) https://doi.org/10.14341/serg12712

Просмотров: 120


ISSN 2306-3513 (Print)
ISSN 2310-3965 (Online)